We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
69.19 USD -3.42 ( 4.71%)
Last update at 2026-11-12T15:41:00Z
VOLUME
148947
Market Cap
6430.86M

Momentum Score

…

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
67.43
Low
72.21
High
52 Week Price Range
35.64
Low
80.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CG Oncology, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer therapies focused on addressing unmet needs in oncology. Its long-term growth drivers include positive clinical trial outcomes, regulatory approvals, strategic partnerships and successful commercialization of its pipeline. Investors may find the company attractive for pipeline potential and exposure to oncology innovation.
The company has no approved products and limited revenue, so its outlook depends on clinical-trial success and access to financing, while regulatory setbacks and intense competition could materially affect prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
72.61
Dividend Yield
-
Revenue TTM
6.23M
Revenue Per Share
0.08
Gross Profit TTM
-161.54M
Debt / Equity
0.01
ROE
-26.41%
Net Debt
-25.47M
ROCE
-21.16%
Diluted EPS TTM
-2.64

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -161.00M -88.04M -48.61M -35.44M -12.84M
Net income -161.00M -88.04M -48.61M -35.44M -12.84M
Selling general administrative 73.53M 33.70M 9.90M 6.41M 4.64M
Gross profit -0.61M 1.14M - - -
Reconciled depreciation 1.45M 0.03M 0.02M 0.01M 0.01M
Ebit -161.00M -114.67M - - -
Ebitda -159.55M -114.63M - - -
Depreciation and amortization 1.45M 0.03M - - -
Operating income -190.77M -114.67M -55.45M -35.25M -12.61M
Other operating expenses 194.81M 115.81M - - -
Interest expense - - - 0.00M 0.45M
Interest income 29.93M 26.62M - - -
Net interest income 29.93M 26.62M 6.90M -0.00M -0.45M
Total revenue 4.04M 1.14M 0.20M 0.19M 10.36M
Total operating expenses 190.17M 115.81M 55.65M 35.44M 22.96M
Cost of revenue 4.65M 0.03M - - -
Total other income expense net 29.78M 26.63M -0.06M -0.20M 0.22M
Net income from continuing ops -161.00M -88.04M -48.61M -35.44M -12.84M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 791.59M 754.80M 199.30M 147.75M 58.69M
Intangible assets 0.57M - - - -
Other current assets 15.07M 11.43M 6.36M 3.42M 4.80M
Total liab 38.99M 21.42M 14.51M 22.57M 101.31M
Total stockholder equity 752.60M 733.38M 184.79M 125.18M -42.62M
Other current liab 24.21M 14.66M 0.45M 0.17M 0.07M
Common stock 0.01M 0.01M - - -
Capital stock 0.01M 0.01M 307.89M 202.87M 0.00M
Retained earnings -378.98M -217.98M -129.94M -81.33M -45.89M
Good will 10.30M - - - -
Cash 32.49M 257.07M 8.27M 88.14M 53.61M
Total current liabilities 30.84M 21.37M 14.25M 15.43M 5.97M
Net debt -25.47M -256.83M - - -
Short term debt 0.92M 0.19M - - -
Short long term debt - - - 8.97M 2.94M
Short long term debt total 7.02M 0.24M - - -
Other stockholder equity 1131.57M 951.35M - - -
Total current assets 759.48M 754.21M 194.12M 147.21M 58.41M
Short term investments 709.66M 484.93M 179.41M 55.34M 0.00M
Net receivables 0.69M 0.78M - - -
Long term debt 3.00M - - 6.53M 12.06M
Inventory 1.56M - - - -
Accounts payable 5.71M 6.52M 3.24M 0.98M 1.00M
Non currrent assets other 1.68M 0.09M 0.02M 0.03M 0.09M
Non current assets total 32.12M 0.59M 5.18M 0.54M 0.28M
Capital lease obligations 4.02M 0.24M 0.46M 0.45M 0.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -223.72M -300.76M -121.19M -55.35M -0.10M
Total cashflows from investing activities -245.82M -300.76M - - -
Net borrowings 0.00M -0.36M - - -
Total cash from financing activities 153.59M 628.28M 87.00M 119.69M 15.45M
Net income -161.00M -88.04M -48.61M -35.44M -12.84M
Change in cash -224.58M 248.80M -79.88M 34.54M 1.70M
Begin period cash flow 257.07M 8.27M 88.14M 53.61M 51.91M
End period cash flow 32.49M 257.07M 8.27M 88.14M 53.61M
Total cash from operating activities -132.35M -78.71M -45.68M -29.80M -13.65M
Issuance of capital stock 147.45M 629.47M 104.63M 119.53M 0.00M
Depreciation 1.45M 0.03M 0.02M 0.01M 0.01M
Change to inventory -0.44M 0.00M - - -
Change to account receivables -0.32M -0.69M - - -
Other cashflows from financing activities 153.59M -0.82M - - -
Capital expenditures 0.13M 0.23M 0.00M 0.01M 0.10M
Change in working capital 2.28M 2.91M 3.44M 4.44M -1.97M
Stock based compensation 26.68M 11.40M 1.53M 0.68M 1.11M
Other non cash items -1.75M -5.01M 0.82M 0.51M 0.40M
Free cash flow -132.48M -78.95M -45.68M -29.82M -13.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
CGON
CG Oncology, Inc. Common stock		 -3.42
4.71%		 69.19 - - 1032.57 6.36 887.38
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

CG Oncology, Inc. Common stock

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

3000 Pegasus Park Drive, Dallas, TX, United States, 75247

949 409 3700

https://cgoncology.com

142

Name Title Year Born
Mr. Arthur Kuan Chairman & CEO 1991
Mr. Ambaw Bellete M.S. President & COO 1971
Dr. Vijay Kasturi M.D. Chief Medical Officer 1968
Ms. Corleen M. Roche CFO & Secretary 1967
Ms. Amy Steele Vice President of Finance, Accounting & Administration NA
Mr. Swapnil Bhargava Ph.D. Chief Technical Officer NA
Mr. Bing Kung Vice President of Corporate Development NA
Mr. Joshua F. Patterson General Counsel & Chief Compliance Officer 1976
Ms. Corleen M. Roche Chief Financial Officer 1967
Mr. Joshua F. Patterson General Counsel, Chief Compliance Officer & Secretary 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…